Overview
This legislation targets the proliferation of highly potent kratom-derived compounds — specifically 7-hydroxymitragynine and mitragynine pseudoindoxyl — that have been sold in convenience stores, gas stations, and similar retail outlets, often marketed as legal alternatives to opioids. The bill's central objective is to draw a sharp regulatory distinction between naturally occurring trace concentrations of these alkaloids in raw or minimally processed kratom products and the synthetically enhanced, concentrated, or chemically converted forms that pose significantly greater abuse and addiction potential. By establishing precise concentration thresholds and conditioning a statutory exemption on compliance with those thresholds, the bill seeks to bring the most dangerous kratom-derived products under the scheduling authority of the Controlled Substances Act while preserving access to traditional kratom products that remain within natural concentration limits. The legislation reflects a targeted public health response to a documented pattern of manufacturers artificially boosting the potency of kratom extracts to levels that mimic the pharmacological profile of opioids.
Key Points
- Targets synthetically enhanced kratom alkaloids sold in retail and convenience store settings
- Distinguishes between naturally occurring alkaloid concentrations and manufactured/concentrated forms
- Establishes binding concentration thresholds as the operative line between exempt and controlled substances
- Preserves access to traditional kratom products meeting natural concentration limits
- Responds to documented public health concerns about opioid-like potency in commercial kratom extracts
Core Provisions
The bill's operative mechanism is a conditional exemption framework embedded within the Controlled Substances Act. Under §2.B, naturally occurring 7-hydroxymitragynine and mitragynine pseudoindoxyl present in Mitragyna speciosa Korth (kratom) or in finished kratom products are exempt from scheduling — but only when strict concentration limits are satisfied. The combined concentration of these two alkaloids, including their salts, isomers, salts of isomers, esters, ethers, and synthetic analogs, must not exceed 1 part per 100 parts mitragynine by mass [§2.B.iii]. For solid, powdered, or encapsulated products, the absolute concentration ceiling is 1 milligram per gram of product [§2.i.i]. For liquid products, the ceiling is 1 milligram per milliliter of product [§2.i.ii]. Any 7-hydroxymitragynine or mitragynine pseudoindoxyl that has been synthesized, chemically converted, concentrated, enriched, isolated, or otherwise produced through manufacturing processes is categorically excluded from the exemption under §2.C, regardless of whether the end concentration would otherwise fall within the thresholds. This manufacturing-process exclusion is absolute and cannot be cured by dilution or reformulation after the fact. The bill also incorporates a functional definition of 'intended for human consumption' at §2.ii, directing that intent be assessed from the totality of circumstances including labeling, advertising, dosage form, method of sale, seller representations, customary use, and evidence of the intended market — a standard that prevents evasion through nominal relabeling as non-consumable products.
Key Points
- Exemption applies only to naturally occurring alkaloids in kratom or finished kratom products [§2.B]
- Combined 7-hydroxymitragynine and mitragynine pseudoindoxyl must not exceed 1 part per 100 parts mitragynine by mass [§2.B.iii]
- Solid/powder/encapsulated products: maximum 1 mg per gram [§2.i.i]
- Liquid products: maximum 1 mg per milliliter [§2.i.ii]
- Any synthesized, converted, concentrated, enriched, or isolated form is categorically excluded from exemption [§2.C]
- Human consumption intent determined by totality of circumstances [§2.ii]
Legal References
- Controlled Substances Act, 21 U.S.C. 801 et seq.
- 21 U.S.C. 813 (analogue substances)
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355
Implementation
Enforcement authority is vested jointly in the Attorney General and the Secretary of Health and Human Services, consistent with the existing dual-agency structure of the Controlled Substances Act. The Attorney General retains the flexibility to proceed under section 203 of the Controlled Substances Act (21 U.S.C. 813), directly under this legislation, or under any other applicable provision of federal law [§2.f], providing broad prosecutorial discretion in selecting the most appropriate legal theory for a given enforcement action. A critical enforcement limitation is established at §3: actions under this section may be based only on the quantity or portion of a substance that is introduced or intended to be introduced into commercial distribution [§3.1], or that is connected to conduct described in subsection (a) [§3.2]. This commercial distribution nexus requirement focuses federal enforcement resources on the supply chain rather than on individual end users, and it prevents enforcement actions predicated solely on personal possession quantities that are not tied to distribution activity. Compliance obligations fall on manufacturers, distributors, and sellers, who must ensure their products do not exceed the specified alkaloid concentration thresholds and that no manufacturing processes have been used to synthesize, concentrate, or chemically convert the regulated alkaloids.
Legal References
- Controlled Substances Act, 21 U.S.C. 801 et seq.
- 21 U.S.C. 813
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355
Impact
The primary beneficiaries of this legislation are consumers who have been exposed to highly potent, opioid-mimicking kratom extracts without adequate warning of their addiction and overdose potential. By removing the most dangerous concentrated products from the legal market, the bill is expected to reduce emergency department visits, addiction cases, and fatalities associated with high-potency kratom alkaloid products. The kratom industry faces significant restructuring: manufacturers and distributors of concentrated extracts, shots, and enhanced products that exceed the statutory thresholds or that rely on manufacturing processes to boost alkaloid content will be required to reformulate or exit the market. Traditional kratom vendors selling leaf powder, capsules, and minimally processed products that naturally fall within the concentration limits will be largely unaffected and may benefit from the removal of high-potency competitors. The administrative burden on compliant manufacturers includes testing and documentation obligations to demonstrate that products meet the concentration thresholds and that no prohibited manufacturing processes were employed. The legislation does not include an explicit appropriations authorization, meaning enforcement will draw on existing DEA and FDA budgetary resources. The effective date tied to the legislative calendar (August 8, 2026) provides the industry with a defined compliance window.
Key Points
- Consumers protected from opioid-potency kratom extracts without adequate safety disclosure
- High-potency extract manufacturers must reformulate or cease distribution
- Traditional kratom vendors selling naturally concentrated products are largely unaffected
- Industry compliance requires alkaloid concentration testing and process documentation
- Enforcement draws on existing DEA and FDA resources without new appropriations
- Compliance deadline tied to August 8, 2026 effective date
Legal Framework
The bill operates as an amendment to the Controlled Substances Act, grounding its authority in Congress's broad Commerce Clause power to regulate the manufacture, distribution, and sale of controlled and potentially controlled substances. The conditional exemption structure — permitting naturally occurring kratom alkaloids below defined thresholds while scheduling manufactured or concentrated forms — is consistent with the existing CSA framework for analogue substances under 21 U.S.C. 813, which the Attorney General may invoke in parallel. The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) provides a complementary regulatory layer, particularly relevant to products marketed with health claims or in dosage forms suggesting drug use. The bill does not contain an explicit federal preemption clause, meaning state kratom regulations — including those enacted under state consumer protection or food safety laws — remain operative to the extent they do not conflict with the federal scheduling determination. The 'intended for human consumption' standard at §2.ii draws on established DEA interpretive practice for analogue substances and is likely to withstand judicial scrutiny given its grounding in objective, observable factors rather than purely subjective seller intent. The commercial distribution nexus requirement at §3 provides a constitutional limiting principle that anchors federal jurisdiction to interstate commerce activity.
Legal References
- U.S. Const. art. I, § 8, cl. 3 (Commerce Clause)
- Controlled Substances Act, 21 U.S.C. 801 et seq.
- 21 U.S.C. 813 (Federal Analogue Act)
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355
- 21 U.S.C. 802 (definitions)
Critical Issues
The most significant implementation challenge is analytical: reliably distinguishing naturally occurring alkaloid concentrations from those achieved through manufacturing processes presents a forensic chemistry problem that current testing methodologies may not resolve with sufficient precision or cost-effectiveness for routine enforcement. A product could theoretically contain alkaloid concentrations within the statutory thresholds while still having been produced through prohibited manufacturing processes, and proving the process rather than merely the concentration will require sophisticated investigative and laboratory resources. The categorical exclusion of any manufactured or concentrated form — regardless of final concentration — creates a strict liability standard that may generate litigation over what constitutes 'manufacturing processes' versus standard agricultural processing, drying, or milling of kratom leaf. Industry opponents will argue that the 1 mg/g and 1 mg/mL thresholds are not grounded in peer-reviewed pharmacological evidence establishing a clear safety boundary, and that the thresholds may effectively ban products that pose no greater risk than those just below the limit. The 'intended for human consumption' standard, while drawn from existing DEA practice, will predictably generate evasion attempts through relabeling and will require sustained enforcement attention. There is also a potential unintended consequence in the form of market displacement: consumers who relied on high-potency kratom products as self-managed opioid withdrawal aids may turn to illicit opioids if compliant lower-potency products prove insufficient for their purposes, potentially worsening public health outcomes in opioid-dependent populations. Finally, the absence of a dedicated funding authorization means enforcement capacity is contingent on agency budget priorities, which may limit the practical reach of the legislation.
Key Points
- Forensic challenge: distinguishing naturally occurring from manufactured alkaloid concentrations in finished products
- Strict liability for manufacturing process exclusion may generate litigation over scope of 'manufacturing processes'
- Concentration thresholds lack explicit grounding in peer-reviewed pharmacological safety data
- Human consumption intent standard will generate evasion through relabeling and require sustained enforcement
- Risk of market displacement to illicit opioids among consumers using high-potency kratom for withdrawal management
- No dedicated funding authorization limits practical enforcement capacity
Legal References
- Controlled Substances Act, 21 U.S.C. 801 et seq.
- 21 U.S.C. 813
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355